Erratum to: Dose-specific adverse drug reaction identification in electronic patient records: Temporal data mining in an inpatient psychiatric population (Drug Safety (2014) 37, (237-247) DOI: 10.1007/s40264-014-0145-z);Dose-specific adverse drug reaction identification in electronic patient records: Temporal data mining in an inpatient psychiatric population

Drug Safety

Volumn 37, Issue 4, 2014, Pages 237-247

  Eriksson, Robert ^a,b   Werge, Thomas ^c   Jensen, Lars Juhl ^a   Brunak, Søren ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; DATA MINING; DOSE RESPONSE; DRUG INFORMATION; ELECTRONIC MEDICAL RECORD; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MENTAL HOSPITAL; MENTAL PATIENT; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; INFORMATION PROCESSING; MALE; MENTAL DISORDERS; MIDDLE AGED; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DATA COLLECTION; DATA MINING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INPATIENTS; MALE; MENTAL DISORDERS; MIDDLE AGED; YOUNG ADULT;

EID: 84898815541     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0158-7     Document Type: Erratum

References (38)

1. Taché SV, Sönnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45:977-89.
2. Van der Hooft CS, Sturkenboom MCJM, van Grootheest K, Kingma HJ, Stricker BHC. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 2006;29:161-8.
3. Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Saljé K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20:626-34.
4. Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother. 2003;4:319-26.
5. World Health Organization. The importance of pharmacovigilance. Geneva: World Health Organization; 2002.
6. Avorn J. Two centuries of assessing drug risks. N Engl J Med. 2012;367:193-7.
7. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov. 2007;6:636-49.
8. Ray WA. Population-based studies of adverse drug effects. N Engl J Med. 2003;23(349):1592-4.
9. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300:2417-9.
10. Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: Wiley; 2007.
11. Gibbons RD, Amatya AK, Brown CH, Hur K, Sue M, Bhaumik DK, et al. Post-approval drug safety surveillance. Annu Rev Public Health. 2010;31:419-37.
12. Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, et al. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf. 2012;21:9-11.
13. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th ed. Chichester: Wiley; 2012.
14. Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427-36.
15. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions a systematic review. Drug Saf. 2006;29:385-96.
16. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol Drug Saf. 2011;20:1-11.
17. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;2(153):600-6.
18. Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet. 2012;13:395-405.
19. Eriksson R, Jensen PB, Frankild S, Jensen LJ, Brunak S. Dictionary construction and identification of possible adverse drug events in Danish clinical narrative text. J Am Med Inf Assoc. 2013;1(20):947-53.
20. Roque FS, Jensen PB, Schmock H, Dalgaard M, Andreatta M, Hansen T, et al. Using electronic patient records to discover disease correlations and stratify patient cohorts. PLoS Comput Biol. 2011;7:e1002141.
21. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2013. 15th ed. Norway: Oslo; 2012.
22. European Medicines Agency. Human medicines. 2012. http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/landing/epar-search.jsp. Accessed 27 Sep 2013
23. Lægemiddelstyrelsen. Produktresuméer - human. 2012. http://www.produktresume.dk/docushare/dsweb/View/Collection-96. Accessed 27 Sep 2013
24. Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36:13-23.
25. Garcia-Serna R, Mestres J. Anticipating drug side effects by comparative pharmacology. Expert Opin Drug Metab Toxicol. 2010;6:1253-63.
26. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792-802.
27. Rang PH, Dale MM, Ritter JM, Flower RJ, Henderson G. Antipsychotic drugs. Rang and Dale's pharmacology. 7th ed. London: Elsevier; 2011. p. 553-63.
28. Meltzer H. Antipsychotic agents & lithium. In: Katzung BG, Masters S, Trevor AJ, editors. Basic and clinical pharmacology. 11th ed. New York: Lange Medical Books/McGraw Hill; 2009. p. 487-507.
29. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf. 2000;22:195-214.
30. Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf. 2010;5:105-11.
31. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Heal Syst Pharm. 2009;1(66):825-33.
32. Pagel JF, Helfter P. Drug induced nightmares: an etiology based review. Hum Psychopharmacol. 2003;18:59-67.
33. Lependu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al. Pharmacovigilance using clinical notes. Clin Pharmacol Ther. 2013;4(93):547-55.
34. Rothschild JM, Mann K, Keohane CA, Williams DH, Foskett C, Rosen SL, et al. Medication safety in a psychiatric hospital. Gen Hosp Psychiatry. 2007;29:156-62.
35. Emmendorfer T, Glassman PA, Moore V, Leadholm TC, Good CB, Cunningham F. Monitoring adverse drug reactions across a nationwide health care system using information technology. Am J Health Syst Pharm. 2012;15(69):321-8.
36. Goldsmith S, Pellmar T, Kleinman A, Bunney W. Reducing suicide: a national imperative. Washington, DC: National Academies Press; 2002. p. 376.
37. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;14(382):951-62.
38. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4:125ra31.